Patent · US Active

Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders

US10561617B2 · kind B2 · utility

0Cited by

1References

27Claims

0Family size

Assignee

EMPROS PHARMA AB · SE

Inventors

Göran Alderborn · Uppsala, SE
Anders Forslund · Uppsala, SE
Ulf Holmbäck · Uppsala, SE
Hans Lennernäs · Uppsala, SE
Jan Stefan Persson Grudén · Uppsala, SE

Key dates

Filing date	Dec 17, 2015
Grant date	Feb 18, 2020
Priority date	—
Expiry date	Dec 17, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P15/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.